Assured Entitlement 保證配額

BLUE FORM 藍表(Assured Entitlement 保證配額)
Please use this Application Form if you are a Qualifying Fosun Pharma H Shareholder and have difficulties applying online via www.eipo.com.hk
閣下如為合資格復星醫藥H股股東且透過www.eipo.com.hk進行網上申請時遇到困難，請使用本申請表格

*This Application Form uses the same terms as defined in the prospectus of Shanghai Henlius Biotech, Inc. (the "**Company**") dated 12 September 2019 (the "**Prospectus**").*
*本申請表格使用上海復宏漢霖生物技術股份有限公司(「**本公司**」)於二零一九年九月十二日刊發的招股章程(「**招股章程**」)所界定的相同詞彙。*

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.
本申請表格及招股章程概不構成在香港以外任何司法權區要約出售或游說要約購買任何香港發售股份。若無根據美國證券法登記或豁免登記，香港發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.
任何根據當地法例不得發送、派發或轉載本申請表格及招股章程的司法權區內概不得發送或派發或轉載(不論方式，亦不論全部或部分)本申請表格及招股章程。

Copies of the Prospectus, all related Application Forms and the other documents specified in the "Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection – Documents Delivered to the Registrar of Companies" section in Appendix VII to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), Hong Kong Securities Clearing Company Limited ("HKSCC"), the Securities and Futures Commission of Hong Kong (the "SFC") and the Registrar of Companies of Hong Kong take no responsibility for the contents of these documents.
招股章程、所有相關申請表格及招股章程附錄七「送呈香港公司註冊處處長及備查文件－送呈公司註冊處處長文件」一節所述的其他文件均已根據香港法例第32章《公司(清盤及雜項條文)條例》第342C條規定送呈香港公司註冊處處長辦理登記。香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對此等文件的內容概不負責。

Ex ess Appli ation 超額申請

BLUE FORM 藍表（Ex ess Appli ation 超額申請）
Please use this Appli ation Form if you are a Qualifying Fosun Pharma H Shareholder and have diffi ulties applying online via www.eipo. om.hk
閣下如為合資格復星醫藥 H 股股東且透過 www.eipo. om.hk 進行網上申請時遇到困難，請使用本申請表格

*This Application Form uses the same terms as defined in the prospectus of Shanghai Henlius Biotech, Inc. (the "**Company**") dated 12 September 2019 (the "**Prospe tus**").*
*本申請表格使用上海復宏漢霖生物技術股份有限公司(「**本公司**」)於二零一九年九月十二日刊發的招股章程(「**招股章程**」)所界定的相同詞彙。*

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.
本申請表格及招股章程概不構成在香港以外任何司法權區要約出售或游說要約購買任何香港發售股份。若無根據美國證券法登記或豁免登記，香港發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.
*任何根據當地法例不得發送、派發或轉載本申請表格及招股章程的司法權區內概不得發送或派發或轉載(不論方旹．焰

Name(s) and address of the Qualifying Fosun Pharma H Shareholder
合資格復星醫藥H股股東姓名／名稱及地址

User ID 使用者編號

A ess Code 通行編號

CCS6535

Apply for Ex ess Reserved Shares

Q ther than your Assured Ent lement, you may apply for excess Reserved Shares. If you intend to apply for excess Reserved Shares, you MUST apply for a number of excess Reserved Shares which is one of the numbers set out in the table below (other than HKSCC Nominees). If you intend to apply for a number of excess Reserved Shares which is not one of the numbers set out in the table below, you MUST apply by using **Blue Form eIPO** only. If you wish to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the **BLUE** Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares applied for or apply through the **Blue Form eIPO** service via **www.eipo. om.hk**.

You need to complete and sign this Application Form and submit one cheque (or banker' s cashier order) for the exact amount of remittance in the table below.

申請超額預留股份

除保證配額外， 閣下亦可申請超額預留股份。倘 閣下擬申請超額預留股份， 閣下必須申請下表中載列的其中一個超額預留股份數目(香港結算代理人除外)。倘 閣下擬申請不在下表中載列的其中一個超額預留股份數目， 閣下必須用**藍表eIPO**申請。倘 閣下擬申請保證配額以外的超額預留股份，則須填妥並簽署申請超額預留股份之**藍色**申請表格，並單獨匯款足額支付所申請超額預留股份的應付股款，或透過**www.eipo. om.hk**使用**藍表eIPO**服務遞交申請。

閣下須填妥及簽署本申請表格並提交一張支票(或銀行本票)支付下表中載列的應付確切金額。

NUMBER OF EXCESS RESERVED SHARES THAT MAY BE APPLIED FOR AND PAYMENTS
可供申請認購的超額預留股份數目及款項

No. of Reserved Shares applied for 申請認購的預留股份數目	Amount payable on appli ation HK$ 申請時應繳款項（港元）	No. of Reserved Shares applied for 申請認購的預留股份數目	Amount payable on appli ation HK$ 申請時應繳款項（港元）	No. of Reserved Shares applied for 申請認購的預留股份數目	Amount payable on appli ation HK$ 申請時應繳款項（港元）	No. of Reserved Shares applied for 申請認購的預留股份數目	Amount payable on appli ation HK$ 申請時應繳款項（港元）
100	5,838.25	2,500	145,956.13	30,000	1,751,473.52	600,000	35,029,470.36
200	11,676.49	3,000	175,147.35	40,000	2,335,298.02	700,000	40,867,715.42
300	17,514.74	3,500	204,338.58	50,000	2,919,122.53	800,000	46,705,960.48
400	23,352.98	4,000	233,529.80	60,000	3,502,947.04	900,000	52,544,205.54
500	29,191.23	4,500	262,721.03	70,000	4,086,771.54	1,000,000	58,382,450.60
600	35,029.47	5,000	291,912.25	80,000	4,670,596.05	1,500,000	87,573,675.90
700	40,867.71	6,000	350,294.70	90,000	5,254,420.55	2,000,000	116,764,901.20
800	46,705.96	7,000	408,677.15	100,000	5,838,245.06	2,500,000	145,956,126.50
900	52,544.20	8,000	467,059.60	200,000	11,676,490.12	3,000,000	175,147,351.80
1,000	58,382.45	9,000	525,442.06	300,000	17,514,735.18	3,500,000	204,338,577.10
1,500	87,573.68	10,000	583,824.51	400,000	23,352,980.24	4,000,000	233,529,802.40
2,000	116,764.90	20,000	1,167,649.01	500,000	29,191,225.30	4,186,000	244,388,938.21

Wr e down oe r e dow .W 0 d w 2 wn

Appli ation Form for Assured Entitlement of Qualifying Fosun Pharma H Shareholders

合資格復星醫藥 H 股股東保證配額申請表格

Mixed Media Offer

The Company wll be relyng on Secton 9A of the Companes (Exemptn of Companes and Prospectuses from Compliance wth Provsns) Notice (Chapter 32L of the Laws of Hong Kong) and wll be ssung the (i) **WHITE** and **YELLOW** Applcaton Forms wthout them beng accompaned by a prnted Prospectus; and (ii) the **ORANGE** Applcaton Forms to the relevant Qualfyng Fosun Internatonal Shareholders and the **BLUE** Applcaton Forms to the relevant Qualfyng Fosun Pharma H Shareholders wthout them beng accompaned by a prnted Prospectus, unless the relevant Qualfyng Fosun Internatonal Shareholders or the relevant Qualfyng Fosun Pharma H Shareholders (as the case may be) have elected to receve corporate communcatons n prnted form under the corporate communcatons polcy of Fosun Internatonal or Fosun Pharma (as the case may be), or have not been asked to elect the means of recevng the corporate communcatons of Fosun Internatonal or Fosun Pharma (as the case may be), n whch case the prnted Prospectus wll be despatched to them separately. The contents of the prnted Prospectus are dentcal to the electronc verson of the Prospectus whch can be accessed and downloaded from the webses of the Company at **www.henlius. om** and the Stock Exchange at **www.hkexnews. hk** under the "*HKExnews > Lsted Company Informaton > Latest Lsted Company Informaton*" secton, respectvely.

Members of the publc, the Qualfyng Fosun Internatonal Shareholders and the Qualfyng Fosun Pharma H Shareholders who wsh to obtan a copy of the prnted Prospectus may obtan a copy, free of charge, upon request durng normal busness hours from 9:00 a.m. on Thursday, 12 September 2019 untl 12:00 noon on Tuesday, 17 September 2019 at the followng locatons:

1. any of the followng branches of the recevng banks of the Company:

   Bank of China (Hong Kong) Limited

Distri t	Bran h Name	Address
Hong Kong Island	Des Voeux Road West Branch	111-119 Des Voeux Road West, Hong Kong
	Cha Wan Branch	Block B, Walton Estate, 341-343 Cha Wan Road, Cha Wan, Hong Kong
Kowloon	Telford, t Cha Wng)	Telforha Wt,34

	Kowloon City Branch	Shop 133, 1/F, Kowloon City Plaza, 18 Hoi Ting Road, Kowloon
New Territories	Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan O, New Territories
	Ma On Shan Plaza Branch	Shop 2103, Level 2, Ma On Shan Plaza, Sai Sha Road, Ma On Shan, New Territories

CMB Wing Lung Bank Limited

District	Branch Name	Address
Hong Kong Island	Head Office	45 Des Voeux Road Central
	Kennedy Town Branch	28 Catchick Street
Kowlоon	Mongkok Branch	B/F CMB Wing Lung Bank Centre, 636 Nathan Road
	Tsim Sha Tsui Branch	4 Carnarvon Road
New Territories	Tsuen Wan Branch	251 Sha Tsui Road

2. any of the following offices of the below Joint Global Coordinators:

China International Capital Corporation Hong Kong Securities Limited
29th Floor, One International Finance Centre
1 Harbour View Street
Central
Hong Kong

Merrill Lynch (Asia Pacific) Limited
Level 55 Cheung Kong Center
2 Queen's Road Central
Central
Hong Kong

BOCI Asia Limited
26th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong

UBS AG Hong Kong Branch
52/F, Two International Finance Centre
8 Finance Street
Central
Hong Kong

CMB International Capital Limited
45/F, Champion Tower
3 Garden Road
Central
Hong Kong

Fosun Hani Securities Limited
Suite 2101-2105 21/F Champion Tower
3 Garden Road
Central
Hong Kong

	奧海城分行	九龍 海庭道18號 奧海城二期 一樓133號
新界	新都城分行	新界 將軍澳 新都城一期 二樓209號
	馬鞍山廣場分行	新界 馬鞍山 西沙路 馬鞍山廣場 L2層2103號

招商永隆銀行有限公司

地區	**分行名稱**	**地址**
香港島	總行	德輔道中45號
	堅尼地城分行	吉席街28號
九龍	旺角分行	彌敦道636號 招商永隆 銀行中心地庫
	尖沙咀分行	加拿分道4號
新界	荃灣分行	沙咀道251號

2. 以下聯席全球協調人的下列任何辦事處：

中國國際金融香港證券有限公司
香港
中環
港景街1號
國際金融中心一期29樓

Merrill Lynch (Asia Pacific) Limited
香港
中環
皇后大道中2號
長江集團中心55樓

中銀國際亞洲有限公司
香港
中環
花園道1號
中銀大廈26樓

UBS AG Hong Kong Branch
香港
中環
金融街8號
國際金融中心二期52樓

招銀國際融資有限公司
香港
中環
花園道3號
冠君大廈45樓

復星恆利證券有限公司
香港
中環
花園道3號
冠君大廈21樓2101-2105室

Sample 樣本

Assured Entitlement 保證配額

BLUE FORM 藍表(Assured Entitlement 保證配額)

Please use this Application Form if you are a Qualifying Fosun Pharma H Shareholder and have difficulties applying online via www.eipo.com.hk

閣下如為合資格復星醫藥H股股東且透過www.eipo.com.hk進行網上申請時遇到困難，請使用本申請表格

3. the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

Details of where printed Prospectuses may be obtained will be displayed prominently at every designated branch of receiving banks where WHITE Application Forms are distributed.

During normal business hours from 9:00 a.m. on Thursday, 12 September 2019 until 12:00 noon on Tuesday, 17 September 2019, at least three copies of the printed Prospectus will be available for inspection at every location where the **WHITE** and **YELLOW** Application Forms are distributed as set out in the section headed "*How to Apply for Hong Kong Offer Shares and Reserved Shares*" in the Prospectus.

3. 香港結算存管處服務櫃檯，地址為香港中環康樂廣場8號交易廣場一座及二座一樓。

可索取招股章程印刷本的地址詳情將於派發白色申請表格的收款銀行各指定分行以顯眼方式展示。

於二零一九年九月十二日(星期四)上午九時正至二零一九年九月十七日(星期二)中午十二時正的正常辦公時間內，在派發**白色**及**黃色**申請表格的各個地點(載於招股章程「*如何申請香港發售股份及預留股份*」)，均有至少三份招股章程印刷本可供查閱。

To: Shanghai Henlius Biotech, Inc.
Joint Sponsors
Joint Global Coordinators
Joint Representatives
Joint Bookrunners
Hong Kong Underwriters

I/We:

- being the Qualifying Fosun Pharma H Shareholder(s) named on this Application Form, **apply** for the number of Reserved Shares specified or deemed to be specified, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association of the Company;
- **enclose** payment in full for the Reserved Shares applied for at the Maximum Offer Price of HK$57.80 per Offer Share (subject to refund), including a 1% brokerage fee, a 0.0027% SFC transaction levy and a 0.005% Stock Exchange trading fee;
- **undertake** and **agree** to accept the Reserved Shares applied for, or any lesser number allotted to me/us on this application;
- **warrant** that this is the only application made by me/us for Reserved Shares for my/our own benefit (other than an application (if any) made in the capacity as a Qualifying Fosun International Shareholder);
- **understand** and **confirm** that these declarations and representations will be relied upon by the Company and the Joint Representatives in deciding whether or not to make any allotment of Reserved Shares to me/ us in response to this application and that I/we may be prosecuted for making a false declaration;
- **authorise** the ompany to pla e m / u name sy on the Share re der ae t holder sy of any Reserved Shares to re allo e/us ders as reCu er t f t f oo t any Share erd cate sy where ppl ar ey and/or any re u d gheCu sy where ppl ar e me/us y d harp osed h 0 u n c to the aqqress sdateo/ n th s ppl cation orm u eo 0 ha appl ed for l l Reserved Shares or /) / o t / e pVo"ed n th s ppl cation o ra tocu enss and to o th s esessary te ar e/u e Shares to ea ocates to me/us and as reCu reory the rt et ssoc ation the ompany

Assured Entitlement 保證配額

BLUE FORM 藍表（Assured Entitlement 保證配額）

Please use this Appli ation Form if you are a Qualifying Fosun Pharma H Shareholder and have diffi ulties applying online via www.eipo. om.hk

閣下如為合資格復星醫藥 H 股股東且透過 www.eipo. om.hk 進行網上申請時遇到困難，請使用本申請表格

- **request** that any refund cheque(s) be made payable to me/ the first-named of us (in the case of joint applicants) in this Application Form;
- **have** read the terms and conditions and application procedures set out on the pages attached to this Application Form and in the Prospectus and agree to be bound by them, and am aware of the restrictions on the Preferential Offering described in the Prospectus;
- **represent**, **warrant** and **undertake** that the allotment of, or application for, the Reserved Shares would not require the Company, the Joint Sponsors, the Joint Global Coordinators, the Joint Representatives the Joint Bookrunners, the Joint Lead Managers or the Underwriters to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
- **represent**, **warrant** and **undertake** that I am not/ we are not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allotted or taking up any Reserved Shares; that I/ we understand that the Reserved Shares have not been and will not be registered under the U.S. Securities Act; and that I/we will acquire the Reserved Shares in an "offshore transaction" (within the meaning of Regulation S under the U.S. Securities Act); and
- **agree** that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.

Warning:

- It is important that you read the terms and conditions and application procedures set out in the Prospectus and in this Application Form.
- You must sign this application in writing (and not by way of personal chop), otherwise the application is liable to be rejected.
- Only one application may be made for the benefit of any person for Reserved Shares on a **BLUE** Application Form. The following are liable to be rejected: multiple or suspected multiple applications for Reserved Shares on the **BLUE** Application Form or through **Blue Form eIPO** service and applications where cheques or banker's cashier orders are dishonoured upon the first presentation.
- You may be prosecuted if you make a false declaration.
- All information stated in this Application Form must be the same as that maintained by Fosun Pharma or any of its wholly-owned subsidiaries.
- **You must omplete this appli ation in English (ex ept Chinese name) unless otherwise stated, otherwise the appli ation is liable to be reje ted.**
- Any alteration to any application detail that you provide on this Application Form should be authorised by the signature of the applicant.
- You or, if you are joint applicants, the first-named applicant must provide your Hong Kong Identity card number/ passport number/Hong Kong business registration certificate number.

- (r (

Ex ess Appli ation 超額申請

BLUE FORM 藍表 (Ex ess Appli ation 超額申請)

Please use this Appli ation Form if you are a Qualifying Fosun Pharma H Shareholder and have diffi ulties applying online via www.eipo. om.hk

閣下如為合資格復星醫藥H股股東且透過www.eipo. om.hk進行網上申請時遇到困難，請使用本申請表格

Appli ation Form for Ex ess Reserved Shares of Qualifying Fosun Pharma H Shareholders
合資格復星醫藥H股股東超額預留股份申請表格

For Qual[illegible]ying Fosun [illegible]harma H Shareholders, appl[illegible]cat[illegible]ons w[illegible]l be accepted unt[illegible] 12:00 noon on Tuesday, 17 September 2019.
You must read the cond[illegible]ons and [illegible]nstruct[illegible]ons attached to th[illegible]s Appl[illegible]cat[illegible]on Form.
To be val[illegible]d, you must complete all appl[illegible]cable parts of th[illegible]s Appl[illegible]cat[illegible]on Form.
[illegible]lease wr[illegible]te clearly [illegible]n Engl[illegible]sh and [illegible]n [illegible]nk.

合資格復星醫藥H股股東的截止接受申請時間為二零一九年九月十

Mixed Media Offer

The Company w[illegible]ll be relyi[illegible]ng on Sect[illegible]on 9A of the Compan[illegible]es (Exempt[illegible]on of Compan[illegible]es and [illegible]rospectuses from Compl[illegible]ance w[illegible]th [illegible]rov[illegible]s[illegible]ons) [illegible]rd[illegible]nance (Chapter 32L of the Laws of Hong Kong) and w[illegible]ll be [illegible]ssu[illegible]ng the (i) **WHITE** and **YELLOW** Appl[illegible]cat[illegible]on Forms w[illegible]thout them be[illegible]ng accompan[illegible]ed by a pr[illegible]nted [illegible]rospectus; and (ii) the **ORANGE** Appl[illegible]cat[illegible]on Forms to the relevant Qual[illegible]fy[illegible]ng Fosun Internat[illegible]onal Shareholders and the **BLUE** Appl[illegible]cat[illegible]on Forms to the relevant Qual[illegible]fy[illegible]ng Fosun [illegible]harma H Shareholders w[illegible]thout them be[illegible]ng accompan[illegible]ed by a pr[illegible]nted [illegible]rospectus, unless the relevant Qual[illegible]fy[illegible]ng Fosun Internat[illegible]onal Shareholders or the relevant Qual[illegible]fy[illegible]ng Fosun [illegible]harma H Shareholders (as the case may be) have elected to rece[illegible]ve corporate commun[illegible]cat[illegible]ons [illegible]n pr[illegible]nted form under the corporate commun[illegible]cat[illegible]ons pol[illegible]cy of Fosun Internat[illegible]onal or Fosun [illegible]harma (as the case may be), or have not been asked to elect the means of rece[illegible]v[illegible]ng the corporate commun[illegible]cat[illegible]ons of Fosun Internat[illegible]onal or Fosun [illegible]harma (as the case may be), [illegible]n wh[illegible]ch case the pr[illegible]nted [illegible]rospectus w[illegible]ll be despatched to them separately. The contents of the pr[illegible]nted [illegible]rospectus are [illegible]dent[illegible]cal to the electron[illegible]c vers[illegible]on of the [illegible]rospectus wh[illegible]ch can be accessed and downloaded from the webs[illegible]es of the Company at **www.henlius. om** and the Stock Exchange at **www.hkexnews.hk** under the "*HKExnews > L[illegible]sted Company Informat[illegible]on > Latest L[illegible]sted Company Informat[illegible]on*" sect[illegible]on, respect[illegible]vely.

Members of the publ[illegible], the Qual[illegible]fy[illegible]ng Fosun Internat[illegible]onal Shareholders and the Qual[illegible]fy[illegible]ng Fosun [illegible]harma H Shareholders who w[illegible]sh to obta[illegible]n a copy of the pr[illegible]nted [illegible]rospectus may obta[illegible]n a copy, free of charge, upon request dur[illegible]ng normal bus[illegible]ness hours from 9:00 a.m. on Thursday, 12 September 2019 unt[illegible] 12:00 noon on Tuesday, 17 September 2019 at the follow[illegible]ng locat[illegible]ons:

1. any of the follow[illegible]ng branches of the rece[illegible]v[illegible]ng banks of the Company:

Bank of China (Hong Kong) Limited

Distri t	Bran h Name	Address
Hong Kong Island	Des Voeux Road West Branch	111-119 Des Voeux Road West, Hong Kong
	Cha[illegible]Wan Branch	Block B, Walton Estate, 341-343 Cha[illegible]Wan Road, Cha[illegible]Wan, Hong Kong
Kowloon	Telford [illegible]laza Branch	Shop [illegible]s [illegible]2-[illegible]7, Telford [illegible]laza, [illegible]o.33 Wa[illegible]Yip Street, Kowloon Bay, Kowloon

混合媒介要約

本公司將依據香港法例第32L章《公司(豁免公司及招股章程遵從條文)公告》第9A條，在(i)並非與招股章程印刷本一併發出的情況下，發出**白色**及**黃色**申請表格；及(ii)並非與招股章程印刷本一併發出的情況下，向相關合資格復星國際股東發出**橙色**申請表格及向相關合資格復星醫藥H股股東發出**藍色**申請表格，除非相關合資格復星國際股東或相關合資格復星醫藥H股股東(視情況而定)已選擇根據復星國際或復星醫藥(視情況而定)公司通訊政策收取公司通訊印刷本或未被要求選擇收取復星國際或復星醫藥(視情況而定)公司通訊稿的方式，在此情況下，招股章程印刷本會分開寄發予彼等。招股章程的印刷本的內容與招股章程的電子版本相同，招股章程的電子版本分別在本公司網站**www.henlius. om**及聯交所網站**www.hkexnews.hk**「*披露易 > 上市公司公告 > 最新上市公司公告*」一欄中可供查閱及下載。

有意索取招股章程印刷本的公眾人士、合資格復星國際股東及合資格復星醫藥H股股東可於二零一九年九月十二日(星期四)上午九時正至二零一九年九月十七日(星期二)中午十二時正的正常辦公時間內，在以下地點免費索取：

1. 本公司收款銀行的下列任何分行：

中國銀行(香港)有限公司

地區	分行名稱	地址
香港島	德輔道西分行	香港德輔道西111-119號
	柴灣分行	香港柴灣道341-343號宏德居B座
九龍	德福廣場分行	九龍灣偉業街33號德福廣場[illegible]2-[illegible]7號舖

BLUE FORM 藍表 (Ex ess Appli ation 超額申請)

Please use this Appli ation Form if you are a Qualifying Fosun Pharma H Shareholder and have diffi ulties applying online via www.eipo. om.hk

閣下如為合資格復星醫藥H股股東且透過www.eipo. om.hk進行網上申請時遇到困難，請使用本申請表格

	lympian City Branch	Shop 133, 1/F, lympian City 2, 18 Hoi Ting Road, Kowloon
New Territories	Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan , New Territories
	Ma n Shan Plaza Branch	Shop 2103, Level 2, Ma n Shan Plaza, Sai Sha Road, Ma n Shan, New Territories

CMB Wing Lung Bank Limited

District	Branch Name	Address
Hong Kong Island	Head Office	45 Des Voeux Road Central
	Kennedy Town Branch	28 Catchick Street
Kowloon	Mongkok Branch	B/F CMB Wing Lung Bank Centre, 636 Nathan Road
	Tsim Sha Tsui Branch	4 Carnarvon Road
New Territories	Tsuen Wan Branch	251 Sha Tsui Road

2. any of the following offices of the below Joint Global Coordinators:

China International Capital Corporation Hong Kong Se urities Limited
29th Floor, ne International Finance Centre
1 Harbour View Street
Central
Hong Kong

Merrill Lyn h (Asia Pa ifi) Limited
Level 55 Cheung Kong Center
2 Queen's Road Central
Central
Hong Kong

BOCI Asia Limited
26th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong

UBS AG Hong Kong Bran h
52/F, Two International Finance Centre
8 Finance Street
Central
Hong Kong

CMB International Capital Limited
45/F, Champion Tower
3 Garden Road
Central
Hong Kong

Fosun Hani Se urities Limited
Suite 2101-2105 21/F Champion Tower
3 Garden Road
Central
Hong Kong

3. the Depository Counter of HKSCC at 1/F, ne & Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

	奧海城分行	九龍 海庭道18號 奧海城二期 一樓133號
新界	新都城分行	新界 將軍澳 新都城一期 二樓209號
	馬鞍山廣場分行	新界 馬鞍山 西沙路 馬鞍山廣場 L2層2103號

@餞界 超簫彔隆銀行有限公司 RæÉ!`4'Ð]Ð %ì, :à ìƒEdRæ

地區	分行名稱	地址
香港島	總行	德輔道中45號
	堅尼地城分行	吉席街28號
九龍	旺角分行	彌敦道636號 招商永隆 銀行中心地庫
	尖沙咀分行	加拿分道4號
新界	荃長彌敦道 1 グ令号酉左号勘 v 鎊令唱餸亂鎬愜齪疮界	

Ex ess Appli ation 超額申請

BLUE FORM 藍表 (Ex ess Appli ation 超額申請)

Please use this Appli ation Form if you are a Qualifying Fosun Pharma H Shareholder and have diffi ulties applying online via www.eipo. om.hk

閣下如為合資格復星醫藥H股股東且透過www.eipo. om.hk進行網上申請時遇到困難，請使用本申請表格

Details of where printed Prospe tuses may be obtained will be displayed prominently at every designated bran h of re eiving banks where WHITE Appli ation Forms are distributed.

During normal business hours from 9:00 a.m. on Thursday, 12 September 2019 until 12:00 noon on Tuesday, 17 September, 2019, at least three copies of the printed Prospectus will be available for inspection at every location where the **WHITE** and **YELLOW** Application Forms are distributed as set out in the section headed "*How to Apply for Hong Kong Offer Shares and Reserved Shares*" in the Prospectus.

可索取招股章程印刷本的地址詳情將於派發白色申請表格的收款銀行各指定分行以顯眼方式展示。

於二零一九年九月十二日(星期四)上午九時正至二零一九年九月十七日(星期二)中午十二時正的正常辦公時間內，在派發**白色**及**黃色**申請表格的各個地點(載於招股章程「*如何申請香港發售股份及預留股份*」)，均有至少三份招股章程印刷本可供查閱。

To: Shanghai Henlius Biotech, Inc.
Joint Sponsors
Joint Global Coordinators
Joint Representatives
Joint Bookrunners
Hong Kong Underwriters

致： 上海復宏漢霖生物技術股份有限公司
聯席保薦人
聯席全球協調人
聯席代表
聯席賬簿管理人
香港包銷商

I/We:

本人／我們：

- being the Qualifying Fosun Pharma H Shareholder(s) named on this Application Form, **apply** for the number of excess Reserved Shares specified or deemed to be specified, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association of the Company;
- 乃名列本申請表格之合資格復星醫藥H股股東，按照招股章程及本申請表格所載條款及條件以及在　貴公司章程細則規限下，**申請**所指定或視作指定數目之超額預留股份；
- **enclose** payment in full for the excess Reserved Shares applied for at the Maximum Offer Price of HK$57.80 per Offer Share (subject to refund), including a 1% brokerage fee, a 0.0027% SFC transaction levy and a 0.005% Stock Exchange trading fee;
- **隨附**以最高發售價每股發售股份57.80港元(多繳款項可予退還)計算申請認購超額預留股份所需的全數付款(包括1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費)；
- **undertake** and **agree** to accept the excess Reserved Shares applied for, or any lesser number allotted to me/us on this application;
- **承諾**及**同意**接納本人／我們就本申請所申請認購的超額預留股份，或獲配發的任何較少數目；
- **warrant** that this is the only application made by me/us for excess Reserved Shares for my/our own benefit (other than an application (if any) made in the capacity as a Qualifying Fosun International Shareholder);
- **保證**是項申請乃本人／我們就超額預留股份為本人／我們本身利益作出之唯一申請(除以合資格復星國際股東身份作出的申請(如有)外)；
- **understand** and **confirm** that these declarations and representations will be relied upon by the Company and the Joint Representatives in deciding whether or not to make any allotment of excess Reserved Shares to me/ us in response to this application and that I/we may be prosecuted for making a false declaration;
- **明白**及**確認**　貴公司及聯席代表將依賴該等聲明及陳述，以決定是否就本申請向本人／我們配發任何超額預留股份，而本人／我們如果作出虛假聲明可能會被檢控；
- **authorise** the Company to place my/our name(s) on the H Share register as the holder(s) of any excess Reserved Shares to be allotted to me/us and such other registers as required under the Articles of Association of the Company, and despatch any Share certificate(s) (where applicable) and/or any refund cheque(s) (where applicable) to me/us by ordinary post at my/ our own risk to the address stated in this Application Form unless I/we have applied for 1,000,000 excess Reserved Shares or more and I/we am/are eligible to collect any Share certificate(s) and/or any refund cheque (where applicable) personally, as provided in this Application Form;
- **授權**　貴公司將本人／我們的姓名／名稱列入H股股東名冊內，作為將配發予本人／我們的任何超額預留股份的持有人，及根據　貴公司章程細則規定的其他登記冊內，並按本申請表格上所示地址以普通郵遞方式向本人／我們寄發任何股票(如適用)及／或任何退款支票(如適用)，郵誤風險概由本人／我們自行承擔(除非本人／我們申請1,000,000股或以上超額預留股份，且本人／我們符合資格按本申請表格所述親自領取任何股票及／或任何退款支票(如適用))；
- **undertake** to sign all documents and to do all things necessary to enable me/us to be registered as the holder of the excess Reserved Shares to be allocated to me/ us, and as required by the Articles of Association of the Company;
- **承諾**簽署所有文件並採取所有必要的事宜，以及根據　貴公司章程細則規定讓本人／我們登記為本人／我們獲分配超額預留股份的持有人；

Sample 樣本

- **request** that any refund cheque(s) be made payable to me/the first-named of us (in the case of joint applicants) in this Application Form;
- **have** read the terms and conditions and application procedures set out on the pages attached to this Application Form and in the Prospectus and agree to be bound by them, and am aware of the restrictions on the Preferential Offering described in the Prospectus;
- **represent, warrant** and **undertake** that the allotment of, or application for, the excess Reserved Shares would not require the Company, the Joint Sponsors, the Joint Global Coordinators, the Joint Representatives, the Joint Bookrunners, the Joint Lead Managers or the Underwriters to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
- **represent**, **warrant** and **undertake** that I am not/we are not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allotted or taking up any excess Reserved Shares; that I/we understand that the excess Reserved Shares have not been and will not be registered under the U.S. Securities Act; and that I/we will acquire the excess Reserved Shares in an "offshore transaction" (within the meaning of Regulation S under the U.S. Securities Act); and
- **agree** that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.

Warning:

- It is important that you read the terms and conditions and application procedures set out in the Prospectus and in this Application Form.
- You must sign this application in writing (and not by way of personal chop), otherwise the application is liable to be rejected.
- Only one application may be made for the benefit of any person for excess Reserved Shares on a **BLUE** Application Form. The following are liable to be rejected: multiple or suspected multiple applications for excess Reserved Shares on the **BLUE** Application Form or through **Blue Form eIPO** service and applications where cheques or banker's cashier orders are dishonoured upon the first presentation.
- You may be prosecuted if you make a false declaration.
- All information stated in this Application Form must be the same as that maintained by Fosun Pharma or any of its wholly-owned subsidiaries.
- **You must omplete this appli ation in English (ex ept Chinese name) unless otherwise stated, otherwise the appli ation is liable to be reje ted.**
- Any alteration to any application details that you provide on this Application Form should be authorised by the signature of the applicant.
- You or, if you are joint applicants, the first-named applicant must provide your Hong Kong identity card number/passport number/Hong Kong business registration certificate number.

- **要求**

Conditions of your Appli ation

Unless otherwise stated, terms used in these conditions have the same meanings ascribed thereto in the Prospectus.

A. Who an apply

1. You, the applicant(s), and any person(s) for whose benefit you are applying, must be a Qualifying Fosun Pharma H Shareholder(s) and must be 18 years of age or above.
2. If you are a firm, the application must be in the names of the individual members, not in the name of the firm.
3. If you are a body corporate, the application must be stamped with the company chop (bearing the company name) and signed by a duly authorised officer, who must state his or her representative capacity.
4. Save under the circumstances permitted by the Listing Rules and guidance letters issued by the Stock Exchange, or any relevant waivers that have been granted by the Stock Exchange, you cannot apply for any Reserved Shares if you or (with the exception of HKSCC Nominees) any person(s) for whose benefit you are applying are/is:
   - an existing beneficial owner of Shares in the Company and/or any of its subsidiaries;
   - a director or chief executive of the Company and/or any of the Company's subsidiaries;
   - an associate of any of the above persons;
   - a connected person of the Company or a person who will become a connected person of the Company immediately upon completion of the Global Offering; or
   - a Non-Qualifying Fosun Pharma H Shareholder.

   Non-Qualifying Fosun Pharma H Shareholders are those Fosun Pharma H Shareholders with registered addresses in, or who are otherwise known by Fosun Pharma to be residents of, jurisdictions outside Hong Kong on the Record Date, in respect of whom the directors of Fosun Pharma and the Company, based on the enquiries made by them, consider it necessary or expedient to exclude from the Preferential Offering on account either of the legal restrictions under the laws of the relevant jurisdiction in which the relevant Fosun Pharma H Shareholder is resident or the requirements of spvant jspwsrs jm jeors laclunt l R wsr rsdctn n

BLUE FORM

Please use this Appli ation Form if you are a Qualifying Fosun Pharma H Shareholder and have diffi ulties applying online via www.eipo. om.hk



- (if you are an agent for another person) **warrant** that reasonable enquiries have been made of the beneficial owner that this application is the only application which will be made for the benefit of that other person on a **BLUE**

E. Power of attorney

If your application is made by a person, duly authorised under a valid power of attorney, the Company and the Joint Representatives, as the Company's agent, may accept it at their discretion and on any conditions they think fit, including requiring evidence of the attorney's authority. The Company and the Joint Representatives, as the Company's agents, will have full discretion to reject or accept any application, in full or in part without giving any reason.

F. Determination of Offer Price

The Offer Price is expected to be fixed on or around Tuesday, 17 September 2019. Applicants are required to pay the Maximum Offer Price of HK$57.80 for each Offer Share (subject to refund) together with 1% brokerage fee, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee. If the Offer Price is not agreed among the Company and the Joint Representatives (on behalf of the Underwriters) on or before Tuesday, 24 September 2019, the Global Offering will not proceed and will lapse.

Allotment of Reserved Shares

Subject to the terms and conditions as set out herein and in the Prospectus, the Reserved Shares will be allotted after the application lists close.

The Company expects to announce the Offer Price, the level of indications of interest in the International Offering, the level of applications under the Hong Kong Public Offering and the Preferential Offering, and the basis of allocation of the Hong Kong Offer Shares and the Reserved Shares on Tuesday, 24 September 2019 in South China Morning Post (in English), Hong Kong Economic Times (in Chinese), the website of the Stock Exchange at **www.hkexnews.hk** and the Company's website **www.henlius.com**

2. **Full discretion of the Company, the Joint Representatives, and their respective agents or nominees, to reject or accept your application:**
   The Company and the Joint Representatives or its or their respective agents or nominees, have full discretion to reject or accept any application, or to accept only part of any application. No reasons have to be given for any rejection or acceptance.

3. **If the allotment of Reserved Shares is void:**
   The allotment of Reserved Shares to you will be void if the Listing Committee does not grant permission to list the Shares either:
   - within three weeks from the closing of the application lists; or
   - within a longer period of up to six weeks if the Listing Committee of the Stock Exchange notifies the Company of that longer period within three weeks of the closing date of the application lists.

4. **You will not receive any allotment if:**
   - this Application Form is not completed in accordance with the instructions as stated herein;
   - this Application Form has not been duly signed (only written signatures are acceptable) (or in the case of a joint application, not all applicants have signed);
   - in respect of applicants who are corporate entities, this Application Form has not been duly signed (only written signature is acceptable) by an authorised officer or affixed with a company chop;
   - the cheque/banker's cashier order/this Application Form is defective;
   - this Application Form is not accompanied with a cheque/banker's cashier order or is accompanied by more than one cheque/banker's cashier order for each of the application for Assured Entitlement and excess application for Reserved Shares;
   - the account name on cheque/banker's cashier order is not pre-printed or certified by the issuing bank;
   - the cheque/banker's cashier order is not drawn on a Hong Kong dollar bank account in Hong Kong;
   - this name of the payee [illegible] the c

Refund of your money

If you do not rece ve any Reserved Shares or if your appl cat on is accepted only in part, the Company w ll refund to you your appl cat on money (nclud ng the related 1% brokerage fee, 0.0027% SFC transact on levy and 0.005% Stock Exchange trad ng fee) or the appropr ate port on thereof w thout nterest. If the ffer Pr ce is less than the Max mum ffer Pr ce, the Company w ll refund to you the surplus appl cat on money (nclud ng the related 1% brokerage fee, 0.0027% SFC transact on levy and 0.005% Stock Exchange trad ng fee) w thout nterest. The refund procedures are stated in the "H. Despatch/Collect on of Share Cert f cates/e-Refund Payment Inst tut ons/Refund Cheques" in the "How to Apply for Hong Kong ffer Shares and Reserved Shares" sect on of the Prospectus.

Effe t of the Information You Give to Computershare Hong Kong Investor Servi es Limited

Computershare Hong Kong Investor Serv ces L m ted and ts related bod es' corporate, d rectors, off cers, employees and agents ("**Representatives**") expressly d sclaim and exclude to the max mum extent permitted by law any l ab l ty for any loss or damage suffered or ncurred by the appl cant or any other person or ent ty however caused relat ng n any way to, or connected w th, any nformat on prov ded by or on behalf of the appl cant on or n connect on w th th s document or any serv ces prov ded hereunder, or any other wr tten or oral commun cat on prov ded by or on behalf of the appl cant n connect on w th th s document or any serv ces prov ded hereunder. Th s ncludes, w thout l m tat on, any errors or om ss ons n such nformat on however caused, or the Representat ves or any other person or ent ty plac ng any rel ance on such nformat on or any documentat on, mage, record ng or reproduct on of such nformat on, or ts accuracy, completeness, currency or rel ab l ty.

Personal Data

Personal information olle tion statement

The ma n prov s ons of the Personal Data (Pr vacy) rd nance (Chapter 486 of the Laws of Hong Kong) (the "O rd nance") came nto effect n Hong Kong on December 20, 1996. Th s Personal Information Collect on Statement nforms the appl cant for and holder of the Hong Kong ffer Shares of the pol c es and pract ces of the Company and ts H Share Reg strar n relat on to personal data and the rd nance.

1. **Reasons for the olle tion of your personal data**

   From t me to t me t s necessary for appl cants for secur t es or reg stered holders of secur t es to supply the r latest correct personal data to the Company and ts H Share Reg strar when apply ng for secur t es or transfer ng secur t es nto or out of the r names or n procur ng the serv ces of the H Share Reg strar. Fa lure to supply the requested data may result n your appl cat on for secur t es be ng rejected or n delay or nab l ty of the Company or ts H Share Reg strar to effect transfers or otherw se render the r serv ces. It may also prevent or s or Ryt ay r ues H Ssfers r /C H t rs / H Sh e Reg st e eIe / p t Co pers Ans be L ste te or rKEEE/g// 3 rgt orhers ers 1 t

- the Company or their respective appointed agents such as financial advisors and receiving bankers;
- HKSCC and HKSCC Nominees, who will use the personal data for the purposes of operating CCASS (in cases where the applicants have requested for the Reserved Shares to be deposited into CCASS);
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company and/or the H Share Registrar in connection with the operation of their respective businesses;
- the Stock Exchange, the SFC and any other statutory, regulatory or governmental bodies in Hong Kong or elsewhere; and
- any other persons or institutions with which the holders of securities have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers.

4. **Retention of personal data**

   The Company and its H Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. **Access to and correction of personal data**

   The Ordinance provides the applicants and the holders of securities with rights to ascertain whether the Company or the H Share Registrar holds their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the H Share Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data or for information regarding policies and practices and kinds of data held should be addressed

- show your account name. This name must either be preprinted on the cheque, or be endorsed at the back by a person authorised by the bank. This account name must be the same name as the name on this form. If this is a joint application, the account name must be the same as the name of the first-named applicant;
- be made payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED - HENLIUS BIOTECH PREFERENTIAL OFFER**

申請條件

除另有指明外，此等條件所用詞彙具備招股章程所賦予的相同涵義。

甲. 申請人資格

1. 閣下(申請人)及　閣下為其利益而提出申請的任何人士必須為合資格復星醫藥H股股東並年滿18歲。
2. 如　閣下屬商號，則須以個別成員的名義而非以商號的名義作出申請。
3. 如　閣下屬法人團體，申請表格必須加蓋公司印鑑(附有公司名稱)並由獲正式授權的高級職員簽署，並須註明其代表身份。

1　ãA　ƒ@2 h4 þ d　p

(iii) 多於可用預留股份，則可用預留股份將按與香港公開發售超額認購情況下常用的分配基準一致的分配基準分配，當中認購額較細的申請將獲較高的分配百分比。倘滿足超額申請後有任何剩餘的股份，有關股份將由聯席代表酌情重新分配至國際發售。為補足股份的零碎持有量至一手完整持有量而作出的任何超額申請將不會獲得優先處理。

除上述者外，優先發售將不受國際發售與香港公開發售之間的回補安排所限。未附帶正確金額申請款項的任何申請將視為完全無效且不會向有關申請人配發任何預留股份。

除透過**藍表eIPO**服務(**www.eipo.com.hk**)或**藍色**申請表格申請預留股份外，合資格復星醫藥H股股東亦可使用**白色**或**黃色**申請表格或透過中央結算系統向香港結算發出電子認購指示或透過**白表eIPO**服務作出一份香港發售股份申請。

合資格復星醫藥H股股東根據香港公開發售使用**白色**或**黃色**申請表格或向香港結算發出電子認購指示或透過**白表eIPO**服務申請香港發售股份，在配額或分配方面並無優先權。

合資格復星醫藥H股股東可按其各自於記錄日期每持有132股復星醫藥H股股份的完整倍數獲發保證配額一個預留股份的基準提出申請。於記錄日期持有少於132股復星醫藥H股的合資格復星醫藥H股股東將不會享有預留股份的保證配額，但仍有權透過申請超額預留股份參與優先發售。

丙. 補充資料

倘刊發招股章程的任何補充文件，已提交申請的申請人可能會或可能不會(視乎補充文件所載資料而定)獲通知彼等須確認其申請。如申請人已獲通知但未有根據獲通知的程序確認彼等的申請，則所有未經確認申請將會無效。受上文所規限，申請一經提交即不得撤銷，而申請人將視為根據已按經補充的招股章程提出申請。

丁. 填交本申請表格的效用

本申請表格一經填妥及提交，即表明　閣下(及如屬聯名申請人，即　閣下與聯名申請人共同及個別)本身或(如作為代理人或代名人)代表委託　閣下作為代理人或代名人的每名人士：

- **指示**及**授權**本公司及／或聯席代表(或彼等各自的代理或代名人)，根據本公司章程細則的規定，代表　閣下簽立任何過戶表格、成交單據或其他文件，並代表　閣下辦理其他一切必需手續，以完成以　閣下名義登記　閣下獲分配的任何預留股份，或以其他方式令招股章程及本申請表格所述的各項安排落實生效；
- **承諾**簽署所有文件及辦理所有必需手續，以便可按本公司章程細則的規定，讓　閣下登記成為　閣下獲分配的預留股份的持有人；
- **聲明、保證及承諾**　閣下明白預留股份並無亦不會根據《美國證券法》進行登記，而(香港結算代理人除外)　閣下或　閣下作為其代表或為其利益購買預留股份的任何其他人士身處美國境外(定義見S規例)及S規例第902條第(h)(3)段所述的人士；
- **確認**　閣下提出本申請時僅依賴招股章程所載的資料及陳述，而除招股章程任何補充文件所載者外，將不會依賴任何其他資料或陳述；
- **同意**本公司、有關人士或**橙表及藍表eIPO**服務供應商現時及日後均毋須對並非載於招股章程(及其任何補充文件)的任何資料及陳述負責；
- **同意**(在不損害　閣下可能擁有的任何其他權利的情況下)本申請一經接納，即不得因無意的失實陳述而撤銷；
- (如申請由代理代表　閣下提出)**保證**　閣下已向　閣下的代理有效及不可撤回地授予一切必需的權力及授權以提出本申請；
- (如　閣下為他人的代理)**保證**已向實益擁有人作出合理查詢，證實本申請乃為該人士利益以**藍色**申請表格而作出的唯一申請，而　閣下已獲正式授權，以該人士代理的身份簽署本申請表格；
- **同意**　閣下的申請一經接納，　閣下的申請將以本公司公佈的優先發售結果為證明；

Sample樣板

- **保證**本申請所載資料屬真實及準確；
- **同意**向本公司、H股證券登記處、收款銀行、有關人士及**橙表及藍表eIPO**服務供應商披露彼等所需關於　閣下或(香港結算代理人除外)　閣下為其利益提出申請的人士的任何個人資料；
- **保證**在提出申請時，　閣下或　閣下可能代其行事之任何人士為合資格復星醫藥H股股東；
- **聲明、保證及承諾**，在提出本申請時，　閣下及／或(香港結算代理人除外)　閣下可能代其行事之任何人士並非關連人士，亦並非將在緊隨全球發售完成後成為本公司關連人士的人士，而　閣下及／或(香港結算代理人除外)　閣下可能代其行事之任何人士認購預留股份並非直接或間接由本公司的關連人士提供資金，且　閣下及／或(香港結算代理人除外)　閣下可能代其行事之任何人士並非根據本公司關連人士的指示作出預留股份的是次認購；
- **同意**　閣下的申請、接納申請及由此而產生的合約均受香港法例管轄，並按其詮釋；
- **承諾**並**同意**接納所申請的預留股份，或　閣下根據申請所獲分配的任何較少數目；
- **授權**本公司將　閣下的姓名／名稱列入H股股份登記冊，作為　閣下獲分配的任何預留股份的持有人，及根據本公司章程細則規定的本公司股東名冊內，並按本申請表格上所示地址以普通郵遞方式寄發任何股票(如適用)及／或任何退款支票(如適用予　閣下或(如為聯名申請人)本申請表格內排名首位的申請人，郵誤風險概由　閣下自行承擔(除非如　閣下申請1,000,000股或以上預留股份，則可親自領取　閣下的退款支票及股票(如適用))；
- **同意**任何收款銀行，而不限於　閣下遞交申請表格的銀行，可處理　閣下的申請，包括寄發退款支票(如有)；
- **確認**　閣下知悉招股章程所述有關預留股份的優先發售限制；
- **明白**本公司及聯席代表將依賴此等聲明及陳述，以決定是否就　閣下提出的申請向　閣下分配任何預留股份；
- 倘香港境外任何地方的法律適用於　閣下的申請，則　閣下**同意**並**保證**，　閣下已遵守所有該等法律，而本公司或有關人于

己. 釐定發售價

預期發售價於二零一九年九月十七日(星期二)或前後釐定。申請人須繳付每股發售股份57.80港元(多繳款項可予退還)的最高發售價，另加1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費。倘若本公司與聯席代表(代表包銷商)並無於二零一九年九月二十四日(星期二)或之前協定發售價，全球發售將不會進行並將告失效。

預留股份的配發

在本申請表格及招股章程載列的條款及條件規限下，預留股份將於截止辦理申請登記後配發。

本公司預期於二零一九年九月二十四日(星期二)在《南華早報》(英文)、《香港經濟日報》(中文)、聯交所網站(**www.hkexnews.hk**

3. **倘預留股份配發作廢：**
倘上市委員會在下列期間未批准股份上市，則配發予　閣下的預留股份將告作廢：
- 由截止辦理申請登記日期起計三星期內；或
- （倘聯交所上市委員會在截止辦理申請登記日期後三星期內通知本公司延長有關期間）由截止辦理申請登記日期起計最多六星期內。

4. **在下列情況下，　閣下將不獲任何配發：**
- 本申請表格並無按照本申請表格所載指示填妥；
- 本申請表格並無妥為簽署（僅接受親筆簽名）（倘為聯名申請，則未經全部申請人簽署）；
- 就法人團體申請人而言，本申請表格未經獲授權的高級職員妥為簽署（僅接受親筆簽名）或未加蓋公司印鑑；
- 支票／銀行本票／本申請表格有缺陷；
- 本申請表格並無就各份保證配額的申請及預留股份的超額申請附有支票／銀行本票或附有超過一張支票／銀行本票；
- 支票／銀行本票並無預印賬戶名稱或賬戶名稱未經開具銀行證明；
- 支票／銀行本票並非自香港的港元銀行賬戶開出；
- 支票／銀行本票的抬頭人並非「**中國銀行(香港)代理人有限公司－復宏漢霖生物技術優先發售**」；
- 支票並無劃線註明「只准存入抬頭人賬戶」；
- 支票為期票；
- 申請人未正確付款或申請人以支票或銀行本票付款但支票或銀行本票於首次過戶時不獲兌現；
- 申請人名稱／聯名申請的排名首位申請人名稱並非預印名稱或並非由銀行授權人士在支票或銀行本票背書的名稱相同；
- 本申請表格所提供申請資料的更改未獲申請人簽署授權；
- 本公司相信如接納申請，會違反收取本申請表格或申請人地址所在司法權區的適用證券或其他法例、規則或規例；或
- 本公司及聯席代表及其各自的代理或代名人行使酌情權，決定拒絕或接納任何申請，或僅接納部分申請。拒絕或接納申請毋須給予任何理由。

5. 倘　閣下使用**藍色**申請表格申請保證配額，　閣下可申請相等於或少於乙欄所列數目的保證配額的預留股份。倘　閣下擬申請少於　閣下保證配額的預留股份，　閣下**必須**申請**藍色**申請表格一覽表所列數目之一，並相應付款（香港結算代理人除外）。
閣下須就保證配額填妥並簽署**藍色**申請表格，並提交一張支票（或銀行本票），金額須為乙欄所印列的確切金額或**藍色**申請表格一覽表所載的相應應付金額。倘　閣下擬申請並非**藍色**申請表格申請保證配額表中載列的其中一個保證配額數目，　閣下**必須**使用**藍表eIPO**申請。倘　閣下擬申請保證配額以外的超額預留股份，則須填妥並簽署申請超額預留股份之**藍色**申請表格，並單獨匯款足額支付所申請超額預留股份的應付股款，或透過**www.eipo.﹐om.hk**使用**藍表eIPO**服務遞交申請。

6. 倘　閣下使用**藍色**申請表格申請超額預留股份，　閣下**必須**申請**藍色**申請表格一覽表所列超額預留股份數目之一，並相應付款（香港結算代理人除外）。　閣下須就超額預留股份填妥並簽署**藍色**申請表格，並提交一張獨立開出的支票（或銀行本票）支付確切金額。倘　閣下擬申請並非**藍色**申請表格申請超額預留股份表中載列的其中一個保證配額數目，　閣下**必須**使用**藍表eIPO**申請。

7. 倘　閣下擬同時申請保證配額的預留股份及超額預留股份，　閣下必須同時提交保證配額的**藍色**申請表格及超額預留股份的**藍色**申請表格。每份**藍色**申請表格必須附上一張獨

0.0027%證監會交易徵費及0.005%聯交所交易費)。有關退款程序載於招股章程「如何申請香港發售股份及預留股份」一節「H. 發送／領取股票／電子退款指示／退款支票」。

- 任何向本公司及／或H股證券登記處提供與其各自業務營運有關的行政、電訊、電腦、付款或其他服務的代理、承包商或第三方服務供應商；
- 聯交所、證監會及香港或其他地區的任何其他法定、監管或政府機關；及
- 證券持有人與其進行或擬進行交易的任何其他人士或機構，如彼等的銀行、律師、會計師或股票經紀等。

4.

下列情況將導致申請可能不獲受理：

- 支票不符合所有上述規定；或
- 支票首次過戶時不獲兌現。

如以銀行本票繳付款項，該本票必須：

- 為港元；
- 由香港持牌銀行發出，並由發出本票銀行的授權人在本票背面簽署證明　閣下姓名。本票背面所顯示姓名須與本申請表格所填寫的姓名相同。如屬聯名申請，本票背面所示姓名必須與排名首位申請人的姓名相同；
- 註明抬頭人為「**中國銀行(香港)代理人有限公司－復宏漢霖生物技術優先發售**」；
- 劃線註明「只准存入抬頭人賬戶」；及
- 不得為期票。

如　閣下的支票或銀行本票不符合上述所有規定，則　閣下的申請可能遭拒絕受理。

4. 將本申請表格對摺一次，然後投入中國銀行(香港)有限公司及招商永隆銀行有限公司的下列任何一間分行的收集箱：

中國銀行(香港)有限公司

地區	分行名稱	地址
香港島	[illegible]	[illegible]

® ± ¤ H ® g
0 ¥ ¥] ên S œ ¥ ¥ ž) \Ôc € P (ÜÀ „% a #75P